Insider Selling: Tempus AI (NASDAQ:TEM) COO Sells 5,000 Shares of Stock

Key Points

• Tempus AI COO Ryan Fukushima sold 5,000 shares of the company's stock at an average price of $92.32, totaling $461,600, which reduced his holdings by 3.70% to 130,000 shares.
• Tempus AI stock recently surged by 11.0%, reaching $103.25, and has shown significant growth with a 12-month revenue increase of 89.5% year-over-year.
• Institutional investors have increased their stakes in Tempus AI, with holdings rising by up to 3,761.5% for specific firms in the second quarter.

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) COO Ryan Fukushima sold 5,000 shares of Tempus AI stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $92.32, for a total value of $461,600.00. Following the completion of the transaction, the chief operating officer owned 130,000 shares in the company, valued at $12,001,600. This trade represents a 3.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Ryan Fukushima also recently made the following trade(s):

• On Tuesday, August 19th, Ryan Fukushima sold 17,460 shares of Tempus AI stock. The shares were sold at an average price of $74.65, for a total value of $1,303,389.00.

Tempus AI Stock Up 11.0%

TEM traded up $10.24 on Wednesday, hitting $103.25. The company had a trading volume of 13,357,453 shares, compared to its average volume of 11,992,104. The stock has a fifty day moving average price of $76.30 and a 200-day moving average price of $63.89. Tempus AI, Inc. has a 12-month low of $31.36 and a 12-month high of $103.42. The company has a debt-to-equity ratio of 2.58, a quick ratio of 1.43 and a current ratio of 1.54. The stock has a market capitalization of $17.94 billion, a price-to-earnings ratio of -86.76 and a beta of 4.87.

Tempus AI (NASDAQ:TEM - Get Free Report) last posted its earnings results on Friday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. Tempus AI had a negative return on equity of 122.86% and a negative net margin of 20.98%.The company had revenue of $314.64 million for the quarter, compared to analyst estimates of $296.84 million. During the same quarter in the previous year, the firm earned ($6.86) earnings per share. The firm's quarterly revenue was up 89.5% compared to the same quarter last year. Tempus AI has set its FY 2025 guidance at EPS. Analysts predict that Tempus AI, Inc. will post -6.15 EPS for the current fiscal year.

Institutional Investors Weigh In On Tempus AI

Institutional investors and hedge funds have recently modified their holdings of the company. Concord Wealth Partners lifted its holdings in Tempus AI by 308.0% in the second quarter. Concord Wealth Partners now owns 408 shares of the company's stock valued at $26,000 after acquiring an additional 308 shares during the period. GAMMA Investing LLC acquired a new position in Tempus AI in the third quarter valued at approximately $28,000. Allworth Financial LP lifted its holdings in Tempus AI by 5,000.0% in the second quarter. Allworth Financial LP now owns 459 shares of the company's stock valued at $29,000 after acquiring an additional 450 shares during the period. Cherry Tree Wealth Management LLC acquired a new position in Tempus AI in the first quarter valued at approximately $31,000. Finally, SouthState Corp lifted its holdings in Tempus AI by 3,761.5% in the second quarter. SouthState Corp now owns 502 shares of the company's stock valued at $32,000 after acquiring an additional 489 shares during the period. Institutional investors and hedge funds own 24.22% of the company's stock.

Analyst Upgrades and Downgrades

TEM has been the topic of a number of research analyst reports. Needham & Company LLC restated a "buy" rating and set a $70.00 price target on shares of Tempus AI in a research note on Friday, August 8th. Piper Sandler restated a "neutral" rating on shares of Tempus AI in a research note on Friday, August 8th. Weiss Ratings restated a "sell (d-)" rating on shares of Tempus AI in a research note on Wednesday. HC Wainwright boosted their price target on Tempus AI from $90.00 to $98.00 and gave the stock a "buy" rating in a research note on Friday, September 12th. Finally, Bank of America boosted their price target on Tempus AI from $68.00 to $70.00 and gave the stock a "neutral" rating in a research note on Wednesday, June 25th. Seven research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $71.83.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.